MRD dynamics and rates across compartments at the end of cycle 30. The alluvial plots show the MRD kinetics of the intention-to-treat population (A) by flow cytometry in PB from baseline to cycle 31; to the right, MRD response in BM is shown for comparison with MRD response in PB at cycle 31; (B) MRD kinetic by immunoglobulin HTS in cellular DNA and in which negativity cutoff was <10^–6 (MRD6); (C) by CAPP-seq in plasma cfDNA in which negativity cutoff was <10^–3 (uMRD <10^–3). MRD rates by flow cytometry in BM (D), by flow cytometry in PB (E), by immunoglobulin HTS in purified B-cell DNA (F), and CAPP-seq in plasma cfDNA (G). H-MRD, high MRD (>10^–2); L-MRD, low-MRD (10^–4-10^–2); PL, plasma; uMRD, unmeasurable MRD (<10^–4, MRD4).